ReviewPharmacology & therapeutics2009
Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease.
Review in Pharmacology & therapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
161 citing papers in PubMed, 370 citations in OpenAlex.
- Circulating microRNAs and association with methacholine PC20 in the Childhood Asthma Management Program (CAMP) cohort.PloS one · 2017Trial
- Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women's Health Study.Diabetes research and clinical practice · 2010Trial
- Effects of Supplementing the Diets of Mice With Different Concentrations of Conjugated Linoleic Acid on the Anti-Inflammatory Function of the Mammary Gland.Food science & nutrition · 2026Article
- Seasonality of Cytokines in Inflammatory Disease: Exploring Molecular Parallels with the Yellow Emperor's Inner Canon.Biology · 2026Review
- Lung injury, oxidative stress, and impaired functioning in a model of prolonged ozone exposure in female mice are associated with macrophage proinflammatory and profibrotic activation and altered bioenergetics.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- LncRNA GAS5 attenuates COPD pathogenesis by stabilizing p120 catenin to suppress NF-κB-driven inflammation.Respiratory research · 2025Article
- Oral Administration of Limosilactobacillus reuteri KBL346 Ameliorates Influenza Virus A/PR8 Infection in Mouse.Probiotics and antimicrobial proteins · 2025Article
- Asian sand dust exacerbates airway inflammation in a mouse model of asthma.Laboratory animal research · 2025Article
- Article
- Volume-Regulated Anion Channel Complex Modulates Mechano-Electrical Signal Responses in Human Airway Smooth Muscle Shortening.American journal of respiratory cell and molecular biology · 2025Article
- The pediatric ocular surface microbiome in pet-owning households.Current research in microbial sciences · 2025Article
- Discovering the role of microRNAs and exosomal microRNAs in chest and pulmonary diseases: a spotlight on chronic obstructive pulmonary disease.Molecular genetics and genomics : MGG · 2024Review
- circUQCRC2 promotes asthma progression in children by activating the VEGFA/NF-κB pathway by targeting miR-381-3p.The Kaohsiung journal of medical sciences · 2024Article
- Myrtenol Inhalation Mitigates Asthma-Induced Cognitive Impairments: an Electrophysiological, Behavioral, Histological, and Molecular Study.Molecular neurobiology · 2024Article
- Article
- Activation of the IKK2/NF-κB pathway in VSMCs inhibits calcified vascular stiffness in CKD.JCI insight · 2024Article
- Echinochrome exhibits anti-asthmatic activity through the suppression of airway inflammation, oxidative stress, and histopathological alterations in ovalbumin-induced asthma in BALB/c mice.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Review
- Dietary tannic acid attenuates elastase-induced pulmonary inflammation and emphysema in mice.Inflammopharmacology · 2024Article
- Anti-diabetic and anti-inflammatory bioactive hits fromFrontiers in pharmacology · 2024Article
101 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Asthma and chronic obstructive pulmonary disease are inflammatory lung disorders responsible for significant morbidity and mortality worldwide. While the importance of allergic responses in asthma is well known, respiratory viral and bacterial infections and pollutants especially cigarette smoke are important factors in the pathogenesis of both diseases. Corticosteroid treatment remains the first preference of treatment in either disease, however these therapies are not always completely effective, and are associated with side effects and steroid resistance. Due to such limitations, development of new treatments represents a major goal for both the pharmaceutical industry and academic researchers. There are now excellent reasons to promote NF-kappaB signalling intermediates and Rel family proteins as potential therapeutic targets for both asthma and chronic obstructive pulmonary disease. This notion is supported by the fact that much of the underlying inflammation of both diseases independent of stimuli, is mediated at least in part, by NF-kappaB mediated signalling events in several cell types. Also, a range of inhibitors of NF-kappaB signalling intermediates are now available, including DNA oligonucleotides and DNA-peptide molecules that act as NF-kappaB decoy sequences, small molecule inhibitors such as IKK-beta inhibitors, and proteasome inhibitors affecting NF-kappaB signalling, that have either shown promise in animal models or have begun clinical trials in other disorders. This review will focus on the role of NF-kappaB in both diseases, will discuss its suitability as a target, and will highlight recent key studies that support the potential of NF-kappaB as a therapeutic target in these two important inflammatory lung diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.